Who has invested in ATB Therapeutics?

EQT Life Sciences are named among the investors backing ATB Therapeutics.

ATB Therapeutics Funding: $59M Raised, Series A (2024)

ATB Therapeutics funding overview

ATB Therapeutics is based in Gent, Belgium. ATB Therapeutics has raised $59M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in November 2024. The round record for ATB Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include EQT Life Sciences.

ATB Therapeutics at a glance

Total raised: $59M
Latest round: Series A
Latest round date: November 2024
Headquarters: Gent, Belgium
Notable investors: EQT Life Sciences

Frequently asked about ATB Therapeutics funding

How much has ATB Therapeutics raised?: ATB Therapeutics has raised $59M in total disclosed funding across the rounds on record.
Who has invested in ATB Therapeutics?: EQT Life Sciences are named among the investors backing ATB Therapeutics.
What was the latest ATB Therapeutics funding round?: The most recent disclosed round is a Series A, announced in November 2024.
Where is ATB Therapeutics based?: ATB Therapeutics is based in Gent, Belgium.
When did ATB Therapeutics last raise?: The last disclosed ATB Therapeutics round closed in November 2024 at Series A.

Round data for ATB Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Gent and backer lists below.

ATB Therapeutics Funding: $59M Raised, Series A (2024)

ATB Therapeutics funding overview

ATB Therapeutics at a glance

Frequently asked about ATB Therapeutics funding

Companies related to ATB Therapeutics (36)

Browse related funding lists (4)